Evaluation of the safety and efficacy of the new Enova® preloaded monofocal intraocular lens and cartridge injector system in cataract surgery

In this prospective and single-center clinical study, the safety and efficacy of the Enova PGF3 intraocular lens (IOL) and cartridge injector system will be evaluated.

The Enova PGF3 cartridge injector system is designed to be used in cataract surgeries. Cataract patients aged 40 years and older, both male and female, without any serious ocular disease other than cataracts, will undergo IOL implantation following cataract surgery. It is planned to perform a total of 200 implantations with either unilateral or bilateral implantation of the participants' eyes.

Postoperative visual acuity, refraction, patient satisfaction, and adverse events will be monitored during follow-up visits at day 1, week 1, and month 1.

The primary objectives of the study are to achieve an uncorrected distance visual acuity of 20/20 or better, and to maintain an error and complication rate related to the preloaded system below 7.5%. Secondary objectives include evaluating patient satisfaction and assessing whether surgeons find the preloaded system easy to use and if it meets their expectations.

The primary endpoints are refractive stability within ±0.50 D, uncorrected distance visual acuity of 20/20 or better, and a general clinical performance rating of the preloaded system with a score of 95% or higher. Secondary endpoints include the duration of surgery, accuracy of lens positioning, surgical complications, surgeon-reported ease of use, and patient satisfaction survey results meeting expectations.

As a safety parameter, adverse events reported in postoperative surgical reports will be evaluated.

Inclusion Criteria:

• Adults of either sex.

Age 40 years or older.

Willing and able to provide written informed consent and comply with planned study visits and procedures.

Healthy ocular status, with no ocular pathology other than cataract and mild refractive error.

Potential visual acuity of 20/32 (0.2 logMAR) or better in both eyes.

Presence of regular corneal astigmatism suitable for treatment with the study device.

Candidates for uncomplicated cataract surgery using the study device.

Exclusion Criteria:

• Irregular corneal astigmatism (e.g., keratoconus).

Corneal pathology (e.g., scar, dystrophy, pterygium, moderate to severe dry eye).

Monocular conditions (e.g., amblyopia).

Previous corneal surgery, including radial keratotomy, corneal refractive surgery, corneal transplantation, DSAEK, or lamellar keratoplasty.

Previous anterior or posterior segment surgery (e.g., vitrectomy, laser iridotomy).

Diabetic retinopathy.

Macular pathology (e.g., age-related macular degeneration [ARMD], epiretinal membrane [ERM]).

History of retinal detachment.

Surgical complications that may affect study outcomes, such as:

Decentration due to capsulorhexis issues

Improper lens placement

Inadequate or missing postoperative capsular support

Posterior capsular rupture

Vitreous loss

Iris damage (tear, rupture, etc.)

Acute or chronic ocular diseases known to affect visual acuity or study outcomes (e.g., immunosuppressed state, connective tissue disease, clinically significant atopic disease, diabetes, or other systemic or ocular conditions).

Participation in any investigational drug or device study within 30 days prior to study start, or ongoing participation in another study.

Individual participant data will not be shared outside the study.